Matthew T. DiCanio, President and Chief Executive Officer of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a share withholding transaction dated November 4, 2026, to satisfy tax obligations from a restricted stock vesting event.
A Form 4 filed on November 6, 2026 disclosed that Thomas A. Devasia, Executive Vice President, Chief Marketing and Innovation Officer of Concentra Group Holdings Parent, Inc., disposed of 11,806 shares of common stock on November 4, 2026 to satisfy tax obligations arising from …
Director Jason Aryeh filed a Form 4 with the SEC on November 6, 2026, disclosing a sale of Ligand Pharmaceuticals common stock on November 4, 2026.
John Robert Anderson Jr., Executive Vice President and Chief Medical Officer of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a tax-withholding transaction on November 4, 2026, in which 13,080 shares of common stock were withheld at $40.90 …
Mount Logan Capital Inc. Chief Accounting Officer Brandon Thomas Harper filed a Form 4 on November 6, 2026, disclosing the acquisition of 7,080 restricted stock units at no cost under the company's 2025 Omnibus Incentive Plan.
Mount Logan Capital Inc. filed a Form 8-K on November 6, 2026, disclosing the appointment of Brandon Harper, age 33, as Chief Accounting Officer and principal accounting officer, effective November 3, 2026.
Baker Bros. Advisors LP filed a Form 4 with the SEC on November 6, 2026, disclosing five open-market purchases of Madrigal Pharmaceuticals, Inc. common stock totaling 91,806 shares acquired between November 4 and November 6, 2026.
Brandon Thomas Harper, Chief Accounting Officer of Mount Logan Capital Inc., filed an initial statement of beneficial ownership with the SEC on November 6, 2026, disclosing direct holdings as of the event date of November 3, 2026.
Jazz Pharmaceuticals plc SVP and Chief Accounting Officer Patricia Carr filed a Form 4 on November 6, 2026, disclosing transactions in ordinary shares on November 4, 2026, including an option exercise and two open-market sales.
Gilead Sciences, Inc. filed a Schedule 13G with the SEC on November 5, 2026, disclosing beneficial ownership of 2,879,996 shares of Aspen Neuroscience, Inc. common stock, representing 9.9% of the class, based on an event date of October 30, 2026.